Research progress in population pharmacokinetics of immune checkpoint inhibitors in the treatment of malignant tumors
Targeted monoclonal antibody antineoplastic drugs represented by immune checkpoint inhibitors(ICIs)can block the binding of ICIs molecules to their ligands,thereby promoting tumor cell clearance by enhancing T cell immune activity,and demonstrating significant clinical effects in improving the overall survival rate of several malignant tumors with poor prognoses.Population pharmacokinetics(PPK)can describe the pharmacokinetic(PK)characteristics of drugs in specific populations,providing a reference for individualized medication.Currently,there are increasing reports on the PPK of ICIs.This paper reviews the research progress of PPK on common antineoplastic drugs of ICIs,lists the structural parameters and covariates of PPK models for various drugs,and summarizes whether the drug regimen needs to be adjusted according to relevant influencing factors,in order to provide a reference for the rational use of ICIs in clinical practice and their pharmacokinetic-pharmacodynamic(PK-PD)studies.
万方数据
维普
